Wire · operational-macro
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA approved zilurgisertib (Atebrioz), an oral ALK2 inhibitor, for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older, marking it as the third approved therapy for this rare disease. Approval is based on positive phase 2 trial data showing reduced new heterotopic ossification and a favourable safety profile.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 25 Sep 2026 and 4 Oct 2026.
◆ ◆ The Wire takeaway
Zilurgisertib's approval opens the US FOP treatment market for oral ALK2 inhibitors down to age 12. Biotech founders targeting rare genetic diseases can now plan trials and commercial strategies around earlier-age patient segments and oral administration advantages.
◆ Coverage
3 sources · first reported 25 Sep 2026 · latest 4 Oct 2026
◆ Related on Wire
◆ Topics